S Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Kotobuki Pharmaceutical Co., Ltd. (Head Office: Nagano; President & CEO: Akira Tomiyama, Ph.D.; hereafter "Kotobuki") today announced that they have entered into a license agreement on the worldwide rights of development, manufacturing and commercialization of a cholesterol absorption inhibitor, KT6-971 which has been developed by Kotobuki in Japan.Under the terms of the agreement, Shionogi will pay an upfront payment, milestone payments at successful completion of key development phases, and royalties based on net sales to Kotobuki. KT6-971 is a cholesterol absorption inhibitor which was originally discovered by Kotobuki. The compound lowers the blood cholesterol level by selectively inhibiting a cholesterol transporter, Niemann-Pick C1-like 1 (NPC1L1) which is related to absorption of biliary and dietary cholesterol in the small intestine. In Japan, a Phase IIa trial for dyslipidemia treatment has been conducted by Kotobuki. Shionogi is planning to evaluate the efficacy and safety of KT6-971 by further clinical trials under the license agreement with Kotobuki.Shionogi is committing to the treatment of metabolic syndrome as one of its targeted therapeutic areas and is promoting Crestor?, a hypercholesterolemia treatment agent, in Japan. KT6-971 lowers blood cholesterol level by a different mechanism of action from statins, including Crestor?. Shionogi and Kotobuki expect KT6-971 will provide a novel treatment option and a better therapeutic efficacy to more patients with dyslipidemia, who have poorly-controlled blood cholesterol level or insufficient efficacy by the treatment of statins. Through the collaboration with Kotobuki on the development and commercialization of KT6-971, Shionogi will make an effort to contribute to the therapy for metabolic syndrome and other related diseases.
Posts
No comments:
Post a Comment